Literature DB >> 6130864

Alpha-adrenoceptor blockade by labetalol during long-term dosing.

A Semplicini, A C Pessina, G P Rossi, M Hlede, F Morandin.   

Abstract

The hypotensive effect of short-term labetalol, the alpha- and beta-adrenoceptor blocker, is greater in subjects in the orthostatic position, possibly because of the alpha-adrenoceptor blockade. During prolonged use the orthostatic blood pressure fall disappears. To verify whether or not this is due to reduction in alpha-blocking activity, phenylephrine-induced increase in blood pressure was studied in six subjects with mild essential hypertension before and after 3 and 6 days and 1 and 6 mo of continuous treatment with 200 mg labetalol three times a day by mouth. At the same intervals, isoproterenol-induced tachycardia was followed to assess beta-blockade. After 3 days on labetalol, the log dose-response curve of phenylephrine-induced increase in blood pressure shifted to the right and the dose of agonist required to elicit a 20% increase in systolic pressure was 1.7 times that before treatment. There was a progressive decline in the dose of agonist that induced the same increase in pressure so that after 6 mo of continuous labetalol it was the same as control. In contrast, the amount of isoproterenol needed to induce a 20% increase in heart rate was two to three times that before labetalol and did not change throughout 6 mo of therapy. These data indicate a decline in the alpha-adrenoceptor-blocking effect of oral labetalol without concomitant change in the degree of beta-adrenoceptor blockade. This might account for the disappearance of orthostatic hypotension early in the course of treatment and for some decrease in the antihypertensive efficacy of labetalol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6130864     DOI: 10.1038/clpt.1983.33

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.

Authors:  P A van Zwieten
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

2.  Are blood pressure surges associated with sympathetic stimulation aggravated by beta-adrenoceptor antagonist treatment?

Authors:  C R Kumana
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

Review 3.  Pharmacology of antihypertensive agents with multiple actions.

Authors:  P A van Zwieten
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Clinical experience with dual-acting drugs in hypertension.

Authors:  K H Rahn
Journal:  Clin Investig       Date:  1992

6.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

Review 7.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 8.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

9.  Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.

Authors:  Benjamin W Van Tassell; Matthew T Rondina; Franklin Huggins; Edward M Gilbert; Mark A Munger
Journal:  Am Heart J       Date:  2008-06-20       Impact factor: 4.749

10.  Psychological characteristics and responses to antihypertensive drug therapy.

Authors:  Samuel J Mann; Linda M Gerber
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jan-Feb       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.